J&J Drops Alligator’s MAb ADC-1013 After Reviewing Combination Data
The anti-CD40 antibody underperformed in some preclinical cancer combination studies, leading J&J to prioritize other assets. Alligator Bioscience will now advance ADC-1013 while seeking a new partner.
You may also be interested in...
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
FTC returns more than $5.4m to more than 100,000 consumers from "free trial" scam;" Hood College names Nutrition Science Program's founding director; Cremer introduces gummy-counting machine; Herbalife renovates LA headquarters; Arby's and Old Spice team up to fight "meat sweats."
The company announced data from the Phase III SPRING study of Takhzyro in children aged 2-11; there is no approved long-term prophylactic therapy for children under 6.